Bertrand Bourre
YOU?
Author Swipe
View article: Evaluating MRI-Confirmed Relapses as a Novel Primary Endpoint in Multiple Sclerosis Trials
Evaluating MRI-Confirmed Relapses as a Novel Primary Endpoint in Multiple Sclerosis Trials Open
Background Clinically defined relapses are the traditional primary endpoint of randomized control trials (RCTs) in multiple sclerosis (MS), yet a substantial proportion lack new inflammatory lesions. Confirming relapses with brain and spin…
View article: Secondary progression activity monitoring in <scp>MS</scp> despite an early highly active treatment the <scp>SPAM</scp> study
Secondary progression activity monitoring in <span>MS</span> despite an early highly active treatment the <span>SPAM</span> study Open
Background Real‐world data suggest that the early use of highly active therapies (HAT) may reduce the risk of transition to secondary progressive MS (SPMS). However, current knowledge about predictive factors of outcomes needs to be improv…
View article: Evaluation of a deep learning segmentation tool to help detect spinal cord lesions from combined T2 and STIR acquisitions in people with multiple sclerosis
Evaluation of a deep learning segmentation tool to help detect spinal cord lesions from combined T2 and STIR acquisitions in people with multiple sclerosis Open
Objective To develop a deep learning (DL) model for the detection of spinal cord (SC) multiple sclerosis (MS) lesions from both sagittal T2 and short tau inversion recovery (STIR) sequences and to investigate whether such a model could imp…
View article: High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis
High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis Open
Importance Vitamin D deficiency is a risk factor for multiple sclerosis (MS) and is associated with the risk of disease activity, but data on the benefits of supplementation are conflicting. Objective To evaluate the efficacy of high-dose …
View article: Assessing the Risk of Relapse After In Vitro Fertilization in Women With Multiple Sclerosis
Assessing the Risk of Relapse After In Vitro Fertilization in Women With Multiple Sclerosis Open
This study, using a 10-year clinical and administrative dataset, did not find any increased risk of relapse after IVF. The maintenance of disease-modifying therapies until IVF was a determining factor in reducing the risk of relapse.
View article: Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody−Associated Disease
Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody−Associated Disease Open
This study suggests a proinflammatory Th17-dominant profile in non-ON MOGAD patients, with a novel finding of a potential protective role of BAFF on relapses. These results shed new light on the pathogenesis of MOGAD, potentially guiding t…
View article: High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS Open
Importance A recent randomized clinical trial concluded that discontinuing medium-efficacy therapy might be a reasonable option for older patients with nonactive multiple sclerosis (MS), but there is a lack of data on discontinuing high-ef…
View article: Holistic, Long-Term Management of People with Relapsing Multiple Sclerosis with Cladribine Tablets: Expert Opinion from France
Holistic, Long-Term Management of People with Relapsing Multiple Sclerosis with Cladribine Tablets: Expert Opinion from France Open
Cladribine tablets (CladT) has been available for therapeutic use in France since March 2021 for the management of highly active relapsing multiple sclerosis (RMS). This high-efficacy disease-modifying therapy (DMT) acts as an immune recon…
View article: Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis Open
Importance Moderately effective therapies (METs) have been the main treatment in pediatric-onset multiple sclerosis (POMS) for years. Despite the expanding use of highly effective therapies (HETs), treatment strategies for POMS still lack …
View article: COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022
COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022 Open
Background: Epidemiologic studies on coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (pwMS) have focused on the first waves of the pandemic until early 2021. Objectives: We aimed to extend these data from the onset …
View article: Efficacy of dalfampridine in neuromyelitis optica spectrum disorder: A pilot study
Efficacy of dalfampridine in neuromyelitis optica spectrum disorder: A pilot study Open
Objective To assess the efficacy of dalfampridine in patients with neuromyelitis optica spectrum disorder. Methods We included 15 consecutive patients, who were started on a treatment of dalfampridine 10 mg twice daily for 2 weeks. Efficac…
View article: Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder
Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder Open
Serum GFAP, tau, and UCH-L1 levels discriminate between AQP4+NMOSD and DS-NMOSD. The different biomarker profile of AQP4+NMOSD vs DS-NMOSD suggests heterogeneity of diseases within the latter category and provides useful data to improve ou…
View article: Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome
Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome Open
Importance Radiologically isolated syndrome (RIS) represents the earliest detectable preclinical phase of multiple sclerosis (MS) punctuated by incidental magnetic resonance imaging (MRI) white matter anomalies within the central nervous s…
View article: Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis
Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis Open
Importance In patients with multiple sclerosis (MS), factors associated with severe COVID-19 include anti-CD20 therapies and neurologic disability, but it is still unclear whether these 2 variables are independently associated with severe …
View article: Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study
Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study Open
Background: Vaccination in patients with multiple sclerosis (MS) treated with immunosuppressive drugs is highly recommended. Regarding COVID-19 vaccination, no specific concern has been raised. Objectives: We aimed to evaluate if COVID-19 …
View article: Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder
Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder Open
This study provides Class IV evidence that de-escalation of rituximab increases the probability of disease reactivation.
View article: Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference
Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference Open
Using a causal inference approach, we found no evidence of significantly deleterious or beneficial long-term effects of pregnancy on disability. The beneficial effects found in other studies were probably related to a reverse causation bia…
View article: Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica
Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica Open
Introduction: Recent studies suggested that anti-CD20 and fingolimod may be associated with lower anti-spike protein-based immunoglobulin-G response following COVID-19 vaccination. We evaluated if COVID-19 occurred despite vaccination amon…
View article: Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome
Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome Open
This study found that age younger than age 37 years, spinal cord involvement, and gadolinium-enhancing lesions on index MRI scan were associated with earlier clinical disease and relevant to the number of enrolled patients needed to detect…
View article: A meta‐analysis comparing first‐line immunosuppressants in neuromyelitis optica
A meta‐analysis comparing first‐line immunosuppressants in neuromyelitis optica Open
Objective As phase III trials have shown interest in innovative but expensive drugs in the treatment of neuromyelitis optica spectrum disorder (NMOSD), data are needed to clarify strategies in the treatment of neuromyelitis optica (NMO). T…